Anti-SPTLC2 Antibody

Serine palmitoyltransferase 2 (EC 2.3.1.50; UniProt O15270; also known as hLCB2a, LCB 2, LCB2a, Long chain base biosynthesis protein 2, Long chain base biosynthesis protein 2a, Serine-palmitoyl-CoA transferase 2, SPT 2) is encoded by the SPTLC2 (also known as HSAN1C, KIAA0526, NSAN1C, LCB2) gene (Gene ID 9517) in human. Serine palmitoyltransferase (SPT) is a pyridoxal 5′-phosphate (PLP)-dependent enzyme that catalyses the first step of de novo sphingolipids (SLs) biosynthesis, namely the condensation of L-serine with palmitoyl coenzyme-A to generate 3-ketodehydrosphinganine (KDS) that forms the sphingoid base backbone of all SLs. The core human SPT homoenzyme is a membrane-bound heterodimer composed of an hLCB1 (SPTLC1) subunit together with either an hLCB2a (SPTLC2) or an hLCB2b (SPTLC3) subunit. The hLCB1/hLCB2 heterodimer contains a single active site composed of residues from both subunits. hLCB2a and hLCB2b share 68% sequence identity, with hLCB2b being the isotype that is predominantly expressed in the placenta and prefers shorter chain acyl-CoAs (C12 and C14) to generate short-chain SLs. In addition, two human small subunits (ssSPTa and ssSPTb) have been identified and found to maximize the catalytic activity and to confer the acyl-CoA substrate chain-length specificity of the hLCB1/hLCB2 core enzyme. Mutations in hLCB1 and hLCB2a are found in patients with hereditary sensory and autonomic neuropathy type I (HSAN1), an inherited disorder that affects sensory and autonomic neurons due to neurotoxic deoxysphingolipids formation as a result of substrate promiscuity of the mutated SPT enzyme.

~63 kDa observed. 62.92 kDa calculated. Target band size is also reported with a smaller apparent molecular weight of ~58kDa Uncharacterized band(s) may appear in some lysates.

A mixture of two linear peptides corresponding to sequences from the N-terminal region and the C-terminal end of human SPTLC2.

Epitope: N-terminal region and C-terminal end.

Anti-SPTLC2 Antibody is an antibody against SPTLC2 for use in Western Blotting.

Research Category
Signaling

Research Sub Category
Lipid Signaling

Western Blotting Analysis: Representative lots detected SPTLC2 in human placenta tissue homogenates and in various lysates from human cell lines, including embryonic kidney HEK293, hepatocellular carcinoma HepG2, choriocarcinoma JAr and JEG-3 (Hornemann, T., et al. (2007). Biochem. J. 405(1):157-164; Hornemann, T., et al. (2006). J. Biol. Chem. 281(49):37275-37281).

Target-specificity of this antiserum was verified by negative blotting using pre-immune serum and by target band blocking using immunogen peptides (Hornemann, T., et al. (2006). J. Biol. Chem. 281(49):37275-37281).

Rabbit polyclonal antibody serum with 0.05% sodium azide.

Unpurified

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Evaluated by Western Blotting in HepG2 cell lysate.

Western Blotting Analysis: A 1:500 dilution of this antibody detected SPTLC2 in 10 µg of HepG2 cell lysate.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.